About the society
Dear Colleagues,
The Czech Society for Rheumatology (ČRS), a member society of the Czech Medical Association of Jan Evangelista Purkyně (ČLS JEP), is a non-profit professional organization. Since its founding on April 3, 1969, it has brought together rheumatologists, physicians from other specialties, non-physician healthcare professionals, researchers, and other experts interested in rheumatic and musculoskeletal diseases.
The newly elected ČRS Board began its work at its inaugural meeting on January 14, 2026. In a secret ballot, Prof. Ladislav Šenolt, MD, PhD, was re-elected President of the Society; Prof. Pavel Horák, MD, CSc., was elected Scientific Secretary; Prof. Michal Tomčík, MD, PhD, was appointed Vice-President; and Marta Olejárová, MD, CSc., was appointed Treasurer. The other Board members for the 2026–2029 term are Jiří Vencovský, MD, DrSc.; Petr Němec, MD, PhD; Kateřina Bouchalová, MD, PhD; Tomáš Soukup, MD, PhD; Zdeněk Dvořák, MD, PhD; Stanislav Macháček, MD; Heřman Mann, MD, PhD; Hana Šmucrová, MA; Kristýna Bubová, MD, PhD (newly representing the Young Rheumatologists Section); Tomáš Zitko, MD; and Šárka Horáčková Fingerhutová, MD, PhD. A new position was also created on the Board for a representative of a patient organization with an advisory vote. The position is held by Edita Müllerová, Chair of Revma Liga Czech Republic. Her involvement reflects the Society’s commitment to giving greater consideration to patients’ experiences, needs, and priorities when making decisions about the future development of the field. Prof. Zbyněk Hrnčíř, MD, DrSc., remains an Honorary Board Member, and Prof. Karel Pavelka, MD, DrSc., has newly been appointed to the role. Dana Tegzová, MD, became Chair of the Audit Committee. The other Audit Committee members are Šárka Forejtová, MD, and Zdeněk Fojtík, MD, PhD. Natálie Kvítková continues to serve as the Society’s Secretary.
The new Board aims to build on the Society’s long-standing and successful activities in postgraduate education; the organization of professional congresses, conferences, and seminars; publication of the journal Česká revmatologie (Czech Rheumatology); support for young rheumatologists; travel grants; and recognition of high-quality scientific publications. At the same time, it must respond to new challenges, including a shortage of rheumatologists, regional disparities in access to care, long waiting times, an uneven network of outpatient clinics and centers, and increasingly complex funding conditions for modern treatments.
One of the main strategic priorities for this term will therefore be to initiate systematic advocacy for a National Action Plan for Rheumatology and Musculoskeletal Health. The plan should establish a long-term framework for prevention and education, early diagnosis, access to specialist care, the organization and funding of healthcare services, rehabilitation, improving patients’ quality of life, supporting research and education, and the use of digital tools. Its development and promotion will require collaboration with the Czech Ministry of Health, health insurance companies, the State Institute for Drug Control, other professional societies, patient organizations, and representatives of healthcare providers.
A key condition for success will be closer and more regular communication with private-practice rheumatologists, who provide a substantial share of day-to-day patient care. The ČRS must create opportunities for them to participate directly in developing common positions, discussions on reimbursement, care organization, the introduction of new healthcare services, and efforts to address regional access to rheumatology care. Establishing a dedicated section or permanent working platform for outpatient rheumatologists within the ČRS should help achieve this.
To achieve these goals, it will be important to strengthen the Board’s working groups with experts not only from academic centers but also from private practices. These groups should take a more active role in addressing specific priorities, such as access to outpatient care, reimbursement and medicines policy, early diagnosis, clinical guidelines, rare diseases, education, cooperation with other professional societies, registries, and the use of clinical data.
Further development of ATTRA, the national registry of biologic and targeted therapies, will be another major priority. At the beginning of the new term, its Scientific Council will be restructured to become a strong and active body that sets the registry’s long-term research strategy, establishes publication priorities, and coordinates its scientific use. The registry will also establish thematic working groups, whose members will actively contribute to the preparation and implementation of specific analytical and publication projects. The aim is to make better use of available data, involve a wider range of experts and collaborating centers, and increase the quality, frequency, and international reach of ATTRA’s scientific output.
The Society will continue to support the next generation of rheumatologists, harmonize specialist training in cooperation with the accreditation commission, foster interdisciplinary collaboration, and communicate actively with both professional and general audiences. We aim to raise awareness of rheumatology as a modern and promising field and encourage more medical students and young physicians to choose it as a career. Cooperation with patient organizations and non-physician healthcare professionals will also play an important role. These priorities are also in line with the current direction of European professional societies.
The ČRS will continue to represent Czech rheumatology within the European Alliance of Associations for Rheumatology (EULAR), nominate Czech experts to international working groups, and adapt European recommendations and professional initiatives to the conditions in the Czech Republic. This work will include developing clear national diagnostic and treatment guidelines, supporting high-quality education, and involving Czech institutions in international research projects.
The Society’s role, however, extends beyond organizing professional events. It should be an active and trusted representative of the entire field, connecting academic and regional institutions, private practices, young rheumatologists, non-physician healthcare professionals, and patient organizations, and advocating for their shared goals.
I firmly believe that open communication, the active involvement of Society members, the work of expert committees and focused working groups, and a unified, coordinated approach will help improve access to and the quality of care for people with rheumatic and musculoskeletal diseases, while further strengthening the position of Czech rheumatology.
Ladislav Šenolt
President, Czech Society for Rheumatology (ČLS JEP)
July 2026